PMID- 23286841
OWN - NLM
STAT- MEDLINE
DCOM- 20130614
LR  - 20181202
IS  - 1478-3231 (Electronic)
IS  - 1478-3223 (Linking)
VI  - 33 Suppl 1
DP  - 2013 Feb
TI  - Optimal treatment with boceprevir for chronic HCV infection.
PG  - 14-22
LID - 10.1111/liv.12070 [doi]
AB  - There are 160-170 million people with chronic hepatitis C virus (HCV) infection 
      worldwide. The marketing of protease inhibitors (PIs) has been a milestone in the 
      history of HCV therapy. In phase III studies, up to 75% of the patients achieved 
      a sustained virological response (SVR) after triple therapy with 
      pegylated-interferon (PEG-IFN)-alpha, ribavirin (RBV) and boceprevir (BOC). However, 
      triple regimens are more expensive and associated with drug-drug interactions 
      (DDIs) and more adverse events (AEs). According to results in 'real-world' 
      settings, safety seems to be limited, in particular in patients with advanced 
      liver disease. To optimize efficacy while minimizing AEs as well as costs, the 
      optimal treatment strategy must be determined for BOC. Optimizing treatment is 
      based on patient selection, the most efficient treatment design, management of 
      side effects and the challenge of DDIs. Therapy-associated risks, treatment 
      urgency and chances of SVR must all be considered for patient selection. In 
      addition, certain differences between the two approved PIs may help identify the 
      ideal candidates for each HCV PI. Optimal treatment design is based on the 
      results of phase II and III studies, in which different approaches have been 
      tested including 'lead-in' and response-guided strategies. Treatment regimens and 
      stopping rules recommended by the FDA and EMA should normally be followed. Still, 
      there are some cases in which more personalized strategies may be more promising. 
      Management of side effects is a major challenge and plays a crucial role in 
      ensuring safety and adherence.
CI  - (c) 2012 John Wiley & Sons A/S.
FAU - Maasoumy, Benjamin
AU  - Maasoumy B
AD  - Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical 
      School, Hannover, Germany.
FAU - Manns, Michael P
AU  - Manns MP
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Liver Int
JT  - Liver international : official journal of the International Association for the 
      Study of the Liver
JID - 101160857
RN  - 0 (Antiviral Agents)
RN  - 0 (Interferon alpha-2)
RN  - 0 (Interferon-alpha)
RN  - 0 (NS3 protein, hepatitis C virus)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Serine Proteinase Inhibitors)
RN  - 0 (Viral Nonstructural Proteins)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 49717AWG6K (Ribavirin)
RN  - 89BT58KELH 
      (N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide)
RN  - 9DLQ4CIU6V (Proline)
RN  - G8RGG88B68 (peginterferon alfa-2b)
RN  - Q46947FE7K (peginterferon alfa-2a)
SB  - IM
MH  - Antiviral Agents/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Hepacivirus/*drug effects/enzymology/genetics
MH  - Hepatitis C, Chronic/diagnosis/*drug therapy
MH  - Humans
MH  - Interferon alpha-2
MH  - Interferon-alpha/therapeutic use
MH  - Patient Selection
MH  - Polyethylene Glycols/therapeutic use
MH  - Proline/adverse effects/*analogs & derivatives/therapeutic use
MH  - Recombinant Proteins/therapeutic use
MH  - Ribavirin/therapeutic use
MH  - Risk Factors
MH  - Serine Proteinase Inhibitors/adverse effects/*therapeutic use
MH  - Treatment Outcome
MH  - Viral Nonstructural Proteins/antagonists & inhibitors/metabolism
EDAT- 2013/01/11 06:00
MHDA- 2013/06/15 06:00
CRDT- 2013/01/05 06:00
PHST- 2013/01/05 06:00 [entrez]
PHST- 2013/01/11 06:00 [pubmed]
PHST- 2013/06/15 06:00 [medline]
AID - 10.1111/liv.12070 [doi]
PST - ppublish
SO  - Liver Int. 2013 Feb;33 Suppl 1:14-22. doi: 10.1111/liv.12070.